before you make an unbelievable fool of yourself Google the marketsize for wet AMD treatment. The market for GBM n or r is smaller than wet AMD treatment. The price of both treatments is irrelevant
I tell you at MC of between 100-200 millions Outlook
you would be wrong
The reason why I mentioned Outlook is that after UK AND EMA approval Outlook hardly showed an increase in value so far. Nowadays the stock market for nonrevenue biotechs responds almost solely to positive cashflow reports, either via licensing or sales or (rumored) buyout for nonrevenue biotech stocks. Unfortunately, Powers made it very clear at the last ASM that as such for NWBO, for the mid-term future, is out of the question.
You guys are just talking heads.
You can address me as singular Im not royalty.
but what MC would you give to Northwest Bio if DCVax is approved?
as I said most probably there will be no additional information provided by NWBO on how to commercialize DCVAXL. That is the reason I'm 1000% in agreement with Biggers post who, as am I, is FED up with this non-commerce passive keep dilution retail attitude of management.
I want to hear from $NWBO how they’ll get to revenues after MHRA Approval (binary) in a presentation posted to the company’s website. Don’t waste my time yapping the lawsuit, I only care about the Judge’s decision.